Skip to main content
. 2020 Aug 9;10(4):595–601. doi: 10.34172/apb.2020.071

Figure 2.

Figure 2

Effect of miR-193a-5p/paclitaxel on breast cancer MDA-MB-231 cells viability. The cells were adjusted with a different doses of miR-193a-5p, paclitaxel, and combination of miR-193a-5p/paclitaxel. Then, cell viability was evaluated by MTT assay. The data represent mean ± SD (n = 3). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.